• Increase font size
  • Default font size
  • Decrease font size
home | about us | contact us
Search
Search Only:

Search Keyword heb

Total: 50 results found.

... the Burn Center at Vall d’Hebron University Hospital in Barcelona, Spain, one of the authors, said, “The dermaPACE® device fulfills a need in the burn treatment community. It is a new, non-invasive ...
... of the candidate vaccine are immunogenic,with an acceptable safety profile, when used in combination with a BCG-primein healthy adults,regardless of theboosting interval. This immune responseis greater ...
... und unterliegen bestimmten Risiken und Ungewissheiten, die dazu führen können, dass tatsächliche Ergebnisse erheblich von den Inhalten dieser zukunftsgerichteten Aussagen abweichen. Zu ...
... en veelbelovende tekenen van langdurige werkzaamheid heeft in vergelijking met bestaande goedgekeurde behandelingen van patiënten met pulmonale arteriële hypertensie (PAH), hebben United Therapeutics ...
... Annual BIO CEO Investor Conference in New York. Hemispherx Biopharma, Inc. (Amex: HEB), announced that the Company, via its manufacturing subcontractor, received a favorable response from the Food and ...
... utilisateurs pourront aisément naviguer pour s’informer sur notre programme Valeur de la technologie et les événements qu’organise MEDEC, lire nos bulletins mensuels et hebdomadaires ...
... aan aandeelhouders die de aandelen op 1 februari 2010 in hun portefeuille hebben. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en ...
... University of the Negev, Beer Sheeva (Israel) Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (VHIO), Barcelona, (Spain) Erasmus Medical Centre, Rótterdam, (The ...
9. RxNews Recap for Thursday 01-07-10
(Home Page/Home Page)
... Hemispherx Biopharma, Inc. (“Hemispherx” or the “Company”) (AMEX:HEB) concerning possible breaches of fiduciary duty and/or other violations of law by the Hemispherx board of directors, related to public ...
... Up Big AH / Receives FDA Approval for Kalbitor (ecallantide) for acute attacks HAE   $HEB / Hemispherx Tanks AH / FDA Complete Response Letter for Ampligen   $SNTS / Santarus Up Big AH / FDA Approval ...
11. HEB Gets Response Letter From FDA
(Home Page/Home Page)
Officials at Hemispherx Biopharma, Inc. (NYSE Amex: HEB) say they have received a long awaited decision in the form of a Complete Response Letter from the US Food and Drug Administration which describes ...
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) has come out swinging against some of the law firms claiming that they mislead investors.   In a press release this morning, the company claims that the ...
Accusations are heating up in the drama involving Hemispherx Biopharma, Inc (AMEX:HEB) and the law firms trying to go after the well capitalized biotech on behalf of investors. The latest of several ...
Shares of Hemispherx BioPharma, Inc (AMEX:HEB) rebounded slightly on Wednesday morning after sliding down to near the $1 mark on Tuesday- after it was announced that the company would spend the next two ...
... spectrum, shares of Hemispherx Biopharma (AMEX:HEB) reacted negatively after officials said that the company plans to finally complete all outstanding queries from the FDA regarding their application for ...
16. RxNews Recap on Thursday 10-29-09
(Home Page/Home Page)
... in chronic kidney disease patients. Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) and Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, announced they have entered into an exclusive ...
... with the Agency to answer its questions and proceed with the clinical trial. 8.) Hemispherx Biopharma (AMEX: HEB) ($1.53) +325%, 3.4M shares / day, $193M The Ampligen saga continues . . . the latest ...
... (AMEX:HEB) Product: Ampligen Antigenics, Inc. (NASDAQ:AGEN) Product: QS-21 Stimulon Other Technologies Which Combat H1N1 Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) Product: Microcyn® Technology ...
Shareholders of Hemispherx Biopharma (AMEX:HEB) may want to tune in to today's Dr. Oz Show the topic was fatigue, including its most debilitating manifestation, Chronic Fatigue Syndrome (CFS).  ...
... to be the first solution. The choice is yours. The sources: www.theratech.com press releases and website http://www.ftc.gov/bc/hsr/index.shtm http://www.wellsphere.com http://www.scienceblog.com http://www.thebody.com/content/art51405.html ...
...  On 7/7/08, the FDA accepted for review Hemispherx Biopharma’s (AMEX: HEB) ($1.81) NDA for Ampligen to treat chronic fatigue syndrome (CFS), which was originally submitted in October 2007. The NDA for ...
22. FDA Calendar Extreme Trades: 85 Single Digit Stocks
(Premium Content/Subscriber Only Content)
... but this study was not part of the pre-IND meetings.   41.) On 7/7/08, the FDA accepted for review Hemispherx Biopharma’s (AMEX: HEB) ($1.81) NDA for Ampligen to treat chronic fatigue syndrome (CFS), ...
An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's ...
... disorder that affects 17 million people worldwide. Prior this news, BioMedReports had scheduled an interview with Dr. William A. Carter, CEO of Hemispherix Biopharma (AMEX:HEB), whose company is ...
25. Upcoming Special Report [Updated]
(Premium Content/Subscriber Only Content)
... A. Carter, CEO of Hemispherx BioPharma, Inc. (AMEX:HEB) is expected to share some important news about the company's pending FDA decision for Ampligen as a first line treatment for Chronic Fatigue Syndrome ...
26. Flu Stocks
(Home Page/Home Page)
... Flu Vaccine Companies with Adjuvants for Swine Flu Vaccines Antigenics, Inc. (NASDAQ:AGEN) Product: QS-21 Stimulon Hemispherx Biopharma (AMEX:HEB) Product: Ampligen Other Technologies Which Combat ...
... using Live Attenuated Influenza Vaccine (LAIV) technology Sanofi-Aventis SA (NYSE:SNY) Product: Swine Flu Vaccine Companies with Adjuvants for Swine Flu Vaccines Hemispherx Biopharma (AMEX:HEB) ...
28. FDA Calendar Extreme Trades: 40 Stocks Under $5
(Premium Content/Subscriber Only Content)
... WSU.   On 7/22/09, Hemispherx Biopharma (AMEX:HEB) ($1.92) provided guidance that it does not expect a FDA decision on its Ampligen New Drug Application (NDA) until fall 2009. President/CEO Dr. William ...
... (AMEX:HEB) Product: Ampligen Antigenics, Inc. (NASDAQ:AGEN) Product: QS-21 Stimulon Other Technologies Which Combat H1N1 Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) Microcyn® Technology platform ...
... Biopharma (AMEX:HEB) ($2.13) provided guidance that it does not expect a FDA decision on its Ampligen New Drug Application (NDA) until fall 2009. President/CEO Dr. William Carter said staffing problems ...
... Exalgo (a once-daily, extended-release oral formulation of the opiate pain drug hydromorphone). On 7/22/09, (29) Hemispherx Biopharma (AMEX:HEB) ($2.13) provided guidance that it does not expect a FDA ...
... from the FDA to accept the NDA filing, rule on the status of the priority review request, and issue a PDUFA action date for pixantrone. On 7/22/09, Hemispherx Biopharma (AMEX:HEB) provided guidance that ...
... the FDA to accept the NDA filing, rule on the status of the priority review request, and issue a PDUFA action date for pixantrone. On 7/22/09, Hemispherx Biopharma (AMEX:HEB) provided guidance that it ...
... of being acquired by Merck (NYSE:MRK). On 7/22/09, Hemispherx Biopharma (AMEX:HEB) provided guidance that it does not expect a FDA decision on its Ampligen New Drug Application (NDA) until fall 2009. ...
PHILADELPHIA -- Hemispherx Biopharma (NYSE AMEX:HEB) announced today that the Company will extend the time allowed for stockholders to vote on proposal number 3 contained in the proxy for the 2009 Annual ...
... Merck (NYSE:MRK). On 7/22/09, Hemispherx Biopharma (AMEX:HEB) provided guidance that it does not expect a FDA decision on its Ampligen New Drug Application (NDA) until fall 2009. President/CEO Dr. William ...
... GlaxoSmithKline (NYSE:GSK), Baxter (NYSE:BAX), and Sinovac Biotech (AMEX:SVA). Also, Hemispherx Biopharma (AMEX:HEB) is scheduled to provide an update on its flu research initiatives via a teleconference ...
... met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). As Hemispherix Biopharma's (AMEX:HEB) Dr. William ...
... (NYSE:GSK), Baxter (NYSE:BAX), and Sinovac Biotech (AMEX:SVA). Also, Hemispherx Biopharma (AMEX:HEB) is scheduled to provide an update on its flu research initiatives via a teleconference on 7/22/09 at ...
... program, and the data continue to be analyzed and compiled for submission to relevant scientific conferences, peer-reviewed journals and regulatory agencies. Hemispherx Biopharma (AMEX:HEB) ($2.49): ...
PHILADELPHIA-- Hemispherx Biopharma (NYSE AMEX:HEB) will provide an update on its Influenza research initiatives via teleconference on Wednesday, July 22, 2009, at 10:00 AM EDT. Initiatives to be discussed ...
... program, and the data continue to be analyzed and compiled for submission to relevant scientific conferences, peer-reviewed journals and regulatory agencies. Hemispherx Biopharma (AMEX:HEB) ($2.49): Ampligen ...
... for Swine Flu Vaccines Hemispherx Biopharma (AMEX:HEB) Product: Ampligen Antigenics, Inc. (NASDAQ:AGEN) Product: QS-21 Stimulon Other Technologies Which Combat H1N1 Oculus Innovative Sciences, Inc. ...
...  Arena Pharmaceuticals ARNA 3.96 -0.71 (-15.20%) 316.92M Orexigen Therapeutics OREX 5.34 -0.69 (-11.44%) 185.09M Hemispherx BioPharma, Inc HEB 2.00 -0.23 ...
...  Thursday July 9 13:10 - 14:55 Location: 305BC Special Considerations for Multi-Component DNA Vaccine Production Plenary Session 7 Henry Hebel, ...
46. ATS Medical Higher On FDA News
(News/Latest News)
... mitral valves are being treated. Dr. Robert F. Hebeler, Jr., who performed the first implant of the ATS Simulus Semi-Rigid Band at Heart Hospital Baylor in Plano, Texas commented, "This Simulus Semi-Rigid ...
... Cell Lymphoma June Phase 3 Zevalin-BEAM for aggressive lymphoma Sponsor: Sheba Medical Center December Phase 1 / 2 Zevalin with Non Myeloablative Allogeneic ...
... HeartWare International, Inc.(NASDAQ:HTWR) Hemispherx BioPharma, Inc(AMEX:HEB) Hi-Tech Pharmacal Co.(NASDAQ:HITK) Home Diagnostics, Inc.(NASDAQ:HDIX) Impax Laboratories, Inc.(NASDAQ:IPXL) Insmed Incorporated(NASDAQ:INSM) ...
... Treatment in Mantle Cell Lymphoma June Phase 3 Zevalin-BEAM for aggressive lymphoma Sponsor: Sheba Medical Center December Phase 1 / 2 Zevalin with Non Myeloablative Allogeneic Stem Cell Transplant ...
... level of integrity in the research written and I think that’s really lacking in their case.” Last month, Dr. William A. Carter, the CEO of Hemispherx Biopharma (NASDAQ:HEB) angrily reacted to slanted ...

Sign Up For Phone Alerts

Home | Privacy Policy
© 2010 BioMedReports.com. All rights reserved